Figure 1Changes in 24-hour urine protein (a), urinary albumin-creatinine ratio (b), plasma albumin (c), serum creatinine (d), eGFR (e) in the three cases with ARAS during dapagliflozin treatment. UTP: 24-hour urine protein; ACR: urinary albumin-creatinine ratio; Alb: serum albumin; Scr: serum creatinine; eGFR: estimated glomerular filtration rate.
In this report, the good efficacy of dapagliflozin is reported for the first time in ARAS patients with decreased renal function. Proteinuria was decreased steadily after administration of dapagliflozin. No patient discontinued SGLT2i therapy due to safety concerns during the follow-up period of 6 months. Limitations should be acknowledged. First, the included patients were with mild or moderate proteinuria, rather than nephrotic proteinuria. Second, this is just a pilot study, and more high-quality studies with a control arm are needed to verify our results.
In conclusion, the pilot study showed good efficacy and tolerance of half-dose dapagliflozin in AS patients. Application of SGLT2i as an add-on therapy may be considered. A high-quality study with a larger number of patients in full dose is needed in the future.
AcknowledgmentsSupport was provided by National Science Foundation of China (82022010); Beijing Natural Science Foundation (Z190023); CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Ethical Statement
The patients have given consent for their clinical information to be published in the journal.
Data Statement
The data will be available on request.
Supplementary DataReferencesAlport Syndrome: Achieving Early Diagnosis and Treatment.
Am J Kidney Dis. 77: 272-279Chavez E. Rodriguez J. Drexler Y. Fornoni A.Novel Therapies for Alport Syndrome.
Front Med (Lausanne). 9848389Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 383: 1436-1446Article InfoPublication HistoryAccepted: June 24, 2022
Received: June 21, 2022
Publication stageIn Press Journal Pre-ProofFootnotesDisclosure
All the authors declared no conflict of interest.
IdentificationDOI: https://doi.org/10.1016/j.ekir.2022.06.017
Copyright© 2022 International Society of Nephrology. Published by Elsevier Inc.
User License Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse
留言 (0)